Termination of Proposed Reverse Takeover

On 17 August 2023, Ashington Innovation plc announced the signing of a non-binding term sheet with Cell Therapy Limited ("Cell Therapy") to acquire 100% of Cell Therapy's total issued equity in an all-share transaction (the "Transaction"). The Company announces today that it has terminated negotiations in relation to the Transaction and the Transaction will no longer proceed.

Both the Company and Cell Therapy have spent considerable time and effort on the due diligence process, negotiating definitive terms and preparing the required transactional and listing documentation, but given current market conditions it was not certain that the required funding for the Transaction would be available. The Board has therefore concluded that it was no longer in the best interests of shareholders to proceed. As the Company's additional proposed acquisition of Calon Cardio-Technology Limited, announced on 24 August 2023, was conditional on the takeover of Cell Therapy, this acquisition will also no longer proceed.

Ashington's ordinary shares were suspended from trading on 17 August 2023 while the details of the Transaction were finalised and the required information is published, or the Transaction was terminated. As the Transaction has been terminated, the Company will make an application to the FCA to request that the suspension of the trading of ordinary shares be lifted.

The Company will continue to evaluate other acquisition opportunities in the technology sector that it believes will be accretive to shareholder value. A further announcement will be made in due course.